KA/EN
Register
Medicines reference
Search
Search
Product

Dalacin C

Favourites

Clindamycin · Pfizer

2 forms: capsule. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form Dose Frequency Georgia
150 mg, Capsule No label dose in the reference yet - Georgia Yes, human
In force until 05 Apr 2027
Human (Ministry of Health, RAMA)
№ რ-034857
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Dalacin C 150 mg, Capsule

hard capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Susceptible Gram-positive/anaerobic wound, abscess, oral/dental, skin or bone infection; compatible toxoplasmosis. Not routine dental prophylaxis or empiric Gram-negative coverage.
7.4/10
Good
vetman assessment

Dalacin C

150 mg, hard capsule, human medicine
Assessed clinical scopeDog · Susceptible Gram-positive/anaerobic wound, abscess, oral/dental, skin or bone infection; compatible toxoplasmosis. Not routine dental prophylaxis or empiric Gram-negative coverage. · By mouth
Care settingVeterinary-directed outpatient/inpatient therapy after infection-site assessment and source control; confirm susceptibility when indicated and whole-capsule dose fit before dispensing
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-034857 · Verified on 15 Oct 2026 Off-label use

A credible oral option for selected susceptible Gram-positive and anaerobic infections in dogs, with useful tissue penetration and veterinary evidence. It is not broad-spectrum rescue therapy: confirm the infection, perform source control and use culture/susceptibility when indicated. The exact whole-capsule strength must match the patient rather than be approximated.

Regulatory and scientific credibility8.0/10

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clinical efficacy7.5/10

Oral clindamycin has applicable canine capsule PK, authorised veterinary infection claims and controlled evidence in susceptible canine pyoderma, with strong activity against many Gram-positive cocci and anaerobes. Current stewardship narrows use to a compatible infection and susceptibility context; inducible MLSB resistance, enterococci and aerobic Gram-negative organisms limit empirical breadth, and source control remains essential.

Safety and tolerability7.0/10

Vomiting and diarrhoea occur occasionally; dysbiosis, resistant-organism or yeast overgrowth, hypersensitivity and hepatic/renal abnormalities are recognised. The exact human capsule also carries severe antibiotic-associated colitis and oesophageal-injury warnings. Correct hydration/swallowing, course selection and laboratory monitoring in prolonged or organ-impaired cases give a generally usable margin.

Clinical practicality7.0/10

A stable immediate-release whole capsule is simple for a dog that can swallow it and whose calculated dose is close to 150 mg. It cannot be divided into validated smaller units; small dogs and many q12h regimens need a lower-strength veterinary capsule, liquid or pharmacy-prepared alternative, and every dose should be followed by food or water.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in an animal with clindamycin or lincomycin hypersensitivity. Clindamycin ingestion can cause severe or fatal gastrointestinal disturbance in rabbits, guinea pigs, hamsters, chinchillas, horses and ruminants; prevent access by other household or hospital species.
  • Never dry-pill a cat. Give a capsule with or immediately after food or follow it with an adequate water bolus; stop and investigate dysphagia, regurgitation, gagging, repeated swallowing or reduced appetite because oesophagitis can progress to stricture.
  • Confirm that the infection site and likely organism fit clindamycin, obtain cytology/culture and susceptibility when disease is deep, recurrent, severe, previously treated or response is poor, and reassess promptly. Inducible macrolide-lincosamide resistance can cause failure despite an apparently susceptible result.
  • Clindamycin does not provide reliable aerobic Gram-negative, enterococcal or CNS coverage. Do not use it as undifferentiated broad-spectrum therapy for sepsis, urinary infection, uncomplicated viral respiratory disease or a protected CNS infection; choose therapy from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or after uncomplicated extraction and are not a substitute for radiographs, debridement, drainage or extraction. Reserve clindamycin for significant infection or a specifically justified high-risk perioperative patient.
  • Vomiting and diarrhoea can occur; stop and reassess severe, persistent or bloody diarrhoea, systemic illness, dehydration or abdominal pain. Prolonged therapy can select resistant bacteria or yeast; investigate superinfection rather than automatically extending or combining antibiotics.
  • For prolonged courses—especially around one month—or severe renal/hepatic disease, monitor clinical response, hydration, CBC and hepatic/renal indices. Use added caution with high doses, neonates and concurrent nephrotoxic therapy; stop for hypersensitivity, jaundice or significant laboratory deterioration.
  • Do not combine routinely with chloramphenicol or a macrolide because they can antagonise clindamycin at the 50S ribosomal site. Clindamycin can enhance neuromuscular blockade; flag current anaesthesia and neuromuscular-blocking drugs and monitor ventilation.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established. Use only after an individual benefit-risk assessment; do not infer reproductive safety from the absence of teratogenicity in high-dose rat studies.
  • These exact 150 mg and 300 mg human capsules are labelled to be swallowed whole and are not validated divisible dose units. Do not eyeball capsule powder. If the calculated animal dose does not closely match a whole capsule, select a lower-strength veterinary product, liquid or pharmacy-compounded patient-specific preparation.
Assessment sources
  1. Dalacin C capsule market audit2026
  2. Dalacin C 150 mg SmPC2026
  3. Dalacin 300 mg SmPC2026
  4. Antirobe veterinary SPC2024
  5. AAFP/AAHA stewardship2022
  6. ISCAID pyoderma 20252025
  7. AAHA dental guideline2019
  8. Canine clindamycin capsule PK2005
  9. Feline clindamycin PK1996
  10. Feline capsule oesophageal injury2006
  11. Canine pyoderma RCT1999
  12. Canine/feline toxoplasmosis2000
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Susceptible wound, abscess or oral/dental infection, selected secondary respiratory infection, or compatible toxoplasmosis. Not routine dental prophylaxis, viral URI or empiric Gram-negative coverage.
5.9/10
Weak evidence support
vetman assessment

Dalacin C

150 mg, hard capsule, human medicine
Assessed clinical scopeCat · Susceptible wound, abscess or oral/dental infection, selected secondary respiratory infection, or compatible toxoplasmosis. Not routine dental prophylaxis, viral URI or empiric Gram-negative coverage. · By mouth
Care settingVeterinary-directed outpatient/inpatient therapy after infection-site assessment and source control; confirm susceptibility when indicated and whole-capsule dose fit before dispensing
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-034857 · Verified on 15 Oct 2026 Off-label use

Clindamycin itself has legitimate feline roles, but this high-strength whole human capsule is a poor presentation for the average cat. Use a lower-strength or liquid patient-appropriate form; if any capsule is used, follow immediately with food or water and never substitute antimicrobial therapy for drainage, dental care or diagnosis.

Regulatory and scientific credibility8.0/10

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clinical efficacy7.0/10

Clindamycin has applicable feline oral PK, authorised veterinary wound/oral infection claims and an established clinical role in compatible toxoplasmosis. Direct feline controlled outcome evidence is limited, toxoplasmosis diagnosis is imperfect, and the drug does not provide broad aerobic Gram-negative coverage; drainage, dental treatment and other source control remain essential.

Safety and tolerability5.5/10

GI upset and superinfection are recognised, and cats have a specific serious capsule hazard: five reported cats given dry 75 mg clindamycin capsules developed oesophagitis or stricture. A food or water chaser reduces pill retention but does not make these 150/300 mg whole capsules dose-appropriate; prolonged therapy or renal/hepatic disease also needs monitoring.

Clinical practicality1.0/10

A 150 mg whole capsule greatly exceeds common single doses for an average cat and the exact label requires swallowing whole; unvalidated powder splitting sacrifices dose accuracy. Cats also need an immediate food or water chaser to reduce oesophageal retention, so a 25 mg veterinary capsule, liquid or pharmacy-compounded patient-specific form is normally preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in an animal with clindamycin or lincomycin hypersensitivity. Clindamycin ingestion can cause severe or fatal gastrointestinal disturbance in rabbits, guinea pigs, hamsters, chinchillas, horses and ruminants; prevent access by other household or hospital species.
  • Never dry-pill a cat. Give a capsule with or immediately after food or follow it with an adequate water bolus; stop and investigate dysphagia, regurgitation, gagging, repeated swallowing or reduced appetite because oesophagitis can progress to stricture.
  • Confirm that the infection site and likely organism fit clindamycin, obtain cytology/culture and susceptibility when disease is deep, recurrent, severe, previously treated or response is poor, and reassess promptly. Inducible macrolide-lincosamide resistance can cause failure despite an apparently susceptible result.
  • Clindamycin does not provide reliable aerobic Gram-negative, enterococcal or CNS coverage. Do not use it as undifferentiated broad-spectrum therapy for sepsis, urinary infection, uncomplicated viral respiratory disease or a protected CNS infection; choose therapy from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or after uncomplicated extraction and are not a substitute for radiographs, debridement, drainage or extraction. Reserve clindamycin for significant infection or a specifically justified high-risk perioperative patient.
  • Vomiting and diarrhoea can occur; stop and reassess severe, persistent or bloody diarrhoea, systemic illness, dehydration or abdominal pain. Prolonged therapy can select resistant bacteria or yeast; investigate superinfection rather than automatically extending or combining antibiotics.
  • For prolonged courses—especially around one month—or severe renal/hepatic disease, monitor clinical response, hydration, CBC and hepatic/renal indices. Use added caution with high doses, neonates and concurrent nephrotoxic therapy; stop for hypersensitivity, jaundice or significant laboratory deterioration.
  • Do not combine routinely with chloramphenicol or a macrolide because they can antagonise clindamycin at the 50S ribosomal site. Clindamycin can enhance neuromuscular blockade; flag current anaesthesia and neuromuscular-blocking drugs and monitor ventilation.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established. Use only after an individual benefit-risk assessment; do not infer reproductive safety from the absence of teratogenicity in high-dose rat studies.
  • These exact 150 mg and 300 mg human capsules are labelled to be swallowed whole and are not validated divisible dose units. Do not eyeball capsule powder. If the calculated animal dose does not closely match a whole capsule, select a lower-strength veterinary product, liquid or pharmacy-compounded patient-specific preparation.
Assessment sources
  1. Dalacin C capsule market audit2026
  2. Dalacin C 150 mg SmPC2026
  3. Dalacin 300 mg SmPC2026
  4. Antirobe veterinary SPC2024
  5. AAFP/AAHA stewardship2022
  6. ISCAID pyoderma 20252025
  7. AAHA dental guideline2019
  8. Canine clindamycin capsule PK2005
  9. Feline clindamycin PK1996
  10. Feline capsule oesophageal injury2006
  11. Canine pyoderma RCT1999
  12. Canine/feline toxoplasmosis2000
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Clindamycin150 mg
Formulation Type
Capsule
Administration route
By mouth
Manufacturer
Pfizer · United States
Registration
Georgia Yes, human
In force until 05 Apr 2027
Human (Ministry of Health, RAMA)
№ რ-034857
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000570957, PL000570958, PL000570959
Verified on: 16 Oct 2026
 US Yes, human
№ ANDA062644, ANDA062803, NDA050162
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
300 mg, Capsule No label dose in the reference yet - Georgia Yes, human
In force until 05 Apr 2027
Human (Ministry of Health, RAMA)
№ რ-034858
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Dalacin C 300 mg, Capsule

hard capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Susceptible Gram-positive/anaerobic wound, abscess, oral/dental, skin or bone infection; compatible toxoplasmosis. Not routine dental prophylaxis or empiric Gram-negative coverage.
7.3/10
Good
vetman assessment

Dalacin C

300 mg, hard capsule, human medicine
Assessed clinical scopeDog · Susceptible Gram-positive/anaerobic wound, abscess, oral/dental, skin or bone infection; compatible toxoplasmosis. Not routine dental prophylaxis or empiric Gram-negative coverage. · By mouth
Care settingVeterinary-directed outpatient/inpatient therapy after infection-site assessment and source control; confirm susceptibility when indicated and whole-capsule dose fit before dispensing
vetman score 7.3/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-034858 · Verified on 15 Oct 2026 Off-label use

A credible oral option for selected susceptible Gram-positive and anaerobic infections in dogs, with useful tissue penetration and veterinary evidence. It is not broad-spectrum rescue therapy: confirm the infection, perform source control and use culture/susceptibility when indicated. The exact whole-capsule strength must match the patient rather than be approximated.

Regulatory and scientific credibility8.0/10

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clinical efficacy7.5/10

Oral clindamycin has applicable canine capsule PK, authorised veterinary infection claims and controlled evidence in susceptible canine pyoderma, with strong activity against many Gram-positive cocci and anaerobes. Current stewardship narrows use to a compatible infection and susceptibility context; inducible MLSB resistance, enterococci and aerobic Gram-negative organisms limit empirical breadth, and source control remains essential.

Safety and tolerability7.0/10

Vomiting and diarrhoea occur occasionally; dysbiosis, resistant-organism or yeast overgrowth, hypersensitivity and hepatic/renal abnormalities are recognised. The exact human capsule also carries severe antibiotic-associated colitis and oesophageal-injury warnings. Correct hydration/swallowing, course selection and laboratory monitoring in prolonged or organ-impaired cases give a generally usable margin.

Clinical practicality6.5/10

The whole 300 mg capsule can fit some large-dog regimens and reduces pill count at high doses, but cannot be divided into validated smaller units. It is unsuitable for most small/medium dogs and inflexible for dose adjustment; a lower-strength veterinary capsule, liquid or pharmacy-prepared alternative is often needed.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in an animal with clindamycin or lincomycin hypersensitivity. Clindamycin ingestion can cause severe or fatal gastrointestinal disturbance in rabbits, guinea pigs, hamsters, chinchillas, horses and ruminants; prevent access by other household or hospital species.
  • Never dry-pill a cat. Give a capsule with or immediately after food or follow it with an adequate water bolus; stop and investigate dysphagia, regurgitation, gagging, repeated swallowing or reduced appetite because oesophagitis can progress to stricture.
  • Confirm that the infection site and likely organism fit clindamycin, obtain cytology/culture and susceptibility when disease is deep, recurrent, severe, previously treated or response is poor, and reassess promptly. Inducible macrolide-lincosamide resistance can cause failure despite an apparently susceptible result.
  • Clindamycin does not provide reliable aerobic Gram-negative, enterococcal or CNS coverage. Do not use it as undifferentiated broad-spectrum therapy for sepsis, urinary infection, uncomplicated viral respiratory disease or a protected CNS infection; choose therapy from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or after uncomplicated extraction and are not a substitute for radiographs, debridement, drainage or extraction. Reserve clindamycin for significant infection or a specifically justified high-risk perioperative patient.
  • Vomiting and diarrhoea can occur; stop and reassess severe, persistent or bloody diarrhoea, systemic illness, dehydration or abdominal pain. Prolonged therapy can select resistant bacteria or yeast; investigate superinfection rather than automatically extending or combining antibiotics.
  • For prolonged courses—especially around one month—or severe renal/hepatic disease, monitor clinical response, hydration, CBC and hepatic/renal indices. Use added caution with high doses, neonates and concurrent nephrotoxic therapy; stop for hypersensitivity, jaundice or significant laboratory deterioration.
  • Do not combine routinely with chloramphenicol or a macrolide because they can antagonise clindamycin at the 50S ribosomal site. Clindamycin can enhance neuromuscular blockade; flag current anaesthesia and neuromuscular-blocking drugs and monitor ventilation.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established. Use only after an individual benefit-risk assessment; do not infer reproductive safety from the absence of teratogenicity in high-dose rat studies.
  • These exact 150 mg and 300 mg human capsules are labelled to be swallowed whole and are not validated divisible dose units. Do not eyeball capsule powder. If the calculated animal dose does not closely match a whole capsule, select a lower-strength veterinary product, liquid or pharmacy-compounded patient-specific preparation.
Assessment sources
  1. Dalacin C capsule market audit2026
  2. Dalacin C 150 mg SmPC2026
  3. Dalacin 300 mg SmPC2026
  4. Antirobe veterinary SPC2024
  5. AAFP/AAHA stewardship2022
  6. ISCAID pyoderma 20252025
  7. AAHA dental guideline2019
  8. Canine clindamycin capsule PK2005
  9. Feline clindamycin PK1996
  10. Feline capsule oesophageal injury2006
  11. Canine pyoderma RCT1999
  12. Canine/feline toxoplasmosis2000
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Susceptible wound, abscess or oral/dental infection, selected secondary respiratory infection, or compatible toxoplasmosis. Not routine dental prophylaxis, viral URI or empiric Gram-negative coverage.
5.8/10
Weak evidence support
vetman assessment

Dalacin C

300 mg, hard capsule, human medicine
Assessed clinical scopeCat · Susceptible wound, abscess or oral/dental infection, selected secondary respiratory infection, or compatible toxoplasmosis. Not routine dental prophylaxis, viral URI or empiric Gram-negative coverage. · By mouth
Care settingVeterinary-directed outpatient/inpatient therapy after infection-site assessment and source control; confirm susceptibility when indicated and whole-capsule dose fit before dispensing
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-034858 · Verified on 15 Oct 2026 Off-label use

Clindamycin itself has legitimate feline roles, but this high-strength whole human capsule is a poor presentation for the average cat. Use a lower-strength or liquid patient-appropriate form; if any capsule is used, follow immediately with food or water and never substitute antimicrobial therapy for drainage, dental care or diagnosis.

Regulatory and scientific credibility8.0/10

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clinical efficacy7.0/10

Clindamycin has applicable feline oral PK, authorised veterinary wound/oral infection claims and an established clinical role in compatible toxoplasmosis. Direct feline controlled outcome evidence is limited, toxoplasmosis diagnosis is imperfect, and the drug does not provide broad aerobic Gram-negative coverage; drainage, dental treatment and other source control remain essential.

Safety and tolerability5.5/10

GI upset and superinfection are recognised, and cats have a specific serious capsule hazard: five reported cats given dry 75 mg clindamycin capsules developed oesophagitis or stricture. A food or water chaser reduces pill retention but does not make these 150/300 mg whole capsules dose-appropriate; prolonged therapy or renal/hepatic disease also needs monitoring.

Clinical practicality0.5/10

A 300 mg whole capsule is not a realistic dose unit for an average cat and cannot be divided into validated portions under the exact label. Opening and estimating powder is inaccurate, while dry capsules can cause oesophageal injury; a veterinary liquid, 25 mg capsule or pharmacy-compounded patient-specific form should be selected instead.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in an animal with clindamycin or lincomycin hypersensitivity. Clindamycin ingestion can cause severe or fatal gastrointestinal disturbance in rabbits, guinea pigs, hamsters, chinchillas, horses and ruminants; prevent access by other household or hospital species.
  • Never dry-pill a cat. Give a capsule with or immediately after food or follow it with an adequate water bolus; stop and investigate dysphagia, regurgitation, gagging, repeated swallowing or reduced appetite because oesophagitis can progress to stricture.
  • Confirm that the infection site and likely organism fit clindamycin, obtain cytology/culture and susceptibility when disease is deep, recurrent, severe, previously treated or response is poor, and reassess promptly. Inducible macrolide-lincosamide resistance can cause failure despite an apparently susceptible result.
  • Clindamycin does not provide reliable aerobic Gram-negative, enterococcal or CNS coverage. Do not use it as undifferentiated broad-spectrum therapy for sepsis, urinary infection, uncomplicated viral respiratory disease or a protected CNS infection; choose therapy from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or after uncomplicated extraction and are not a substitute for radiographs, debridement, drainage or extraction. Reserve clindamycin for significant infection or a specifically justified high-risk perioperative patient.
  • Vomiting and diarrhoea can occur; stop and reassess severe, persistent or bloody diarrhoea, systemic illness, dehydration or abdominal pain. Prolonged therapy can select resistant bacteria or yeast; investigate superinfection rather than automatically extending or combining antibiotics.
  • For prolonged courses—especially around one month—or severe renal/hepatic disease, monitor clinical response, hydration, CBC and hepatic/renal indices. Use added caution with high doses, neonates and concurrent nephrotoxic therapy; stop for hypersensitivity, jaundice or significant laboratory deterioration.
  • Do not combine routinely with chloramphenicol or a macrolide because they can antagonise clindamycin at the 50S ribosomal site. Clindamycin can enhance neuromuscular blockade; flag current anaesthesia and neuromuscular-blocking drugs and monitor ventilation.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established. Use only after an individual benefit-risk assessment; do not infer reproductive safety from the absence of teratogenicity in high-dose rat studies.
  • These exact 150 mg and 300 mg human capsules are labelled to be swallowed whole and are not validated divisible dose units. Do not eyeball capsule powder. If the calculated animal dose does not closely match a whole capsule, select a lower-strength veterinary product, liquid or pharmacy-compounded patient-specific preparation.
Assessment sources
  1. Dalacin C capsule market audit2026
  2. Dalacin C 150 mg SmPC2026
  3. Dalacin 300 mg SmPC2026
  4. Antirobe veterinary SPC2024
  5. AAFP/AAHA stewardship2022
  6. ISCAID pyoderma 20252025
  7. AAHA dental guideline2019
  8. Canine clindamycin capsule PK2005
  9. Feline clindamycin PK1996
  10. Feline capsule oesophageal injury2006
  11. Canine pyoderma RCT1999
  12. Canine/feline toxoplasmosis2000
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Clindamycin300 mg
Formulation Type
Capsule
Administration route
By mouth
Manufacturer
Pfizer · United States
Registration
Georgia Yes, human
In force until 05 Apr 2027
Human (Ministry of Health, RAMA)
№ რ-034858
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000570957, PL000570958, PL000570959
Verified on: 16 Oct 2026
 US Yes, human
№ ANDA062644, ANDA062803, NDA050162
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Clindamycin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5.5 mg/kg Dog, Cat Bacterial Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clindaseptin 25 mg/ml Oral Solution for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
11 mg/kg Dog, Cat Bacterial Infection; Skin and Soft Tissue Infection By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clindaseptin 25 mg/ml Oral Solution for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
11 mg/kg Dog Osteomyelitis By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
5.5–33 mg/kg Dog Bacterial Infection By mouth 2 times daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026
11–33 mg/kg Dog Osteomyelitis By mouth 2 times daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026
11–33 mg/kg Cat Bacterial Infection By mouth once daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026

Known Contraindications

  • Critical
    Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations.
    Sources: VMD SPC · VMD
  • Warning
    ingestion of clindamycin by these species may cause severe gastro-intestinal disorders, that can sometimes be fatal.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗